Features of Electronic Health Records Necessary for the Delivery of Optimized Anticoagulant Therapy: Consensus of the EHR Task Force of the New York State Anticoagulation Coalition

Annals of Pharmacotherapy

Volumn 49, Issue 1, 2015, Pages 113-124

  Spyropoulos, Alex C ^a   Viscusi, Anna ^b   Singhal, Nakul ^c   Gilleylen, Jason ^b   Kouides, Peter ^d   Howard, Maureen ^e   Rudd, Kelly ^f   Ansell, Jack ^g   Triller, Darren M ^b  

^a Northwell Health   (United States)

^b IPRO Inc   (United States)

^c LENOX HILL HOSPITAL   (United States)

^d ROCHESTER GENERAL HOSPITAL   (United States)

^e STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

^f BASSETT MEDICAL CENTER   (United States)

^g DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

adverse drug reactions; anticoagulants; anticoagulation; computers; drug safety; electronic information; medical informatics; medication safety; quality assurance; warfarin

Indexed keywords

ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; ARTICLE; BLOOD ANALYSIS; CLINICAL ASSESSMENT; CONSENSUS; DEMOGRAPHY; ELECTRONIC MEDICAL RECORD; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HEALTH SERVICE; HOSPITAL DISCHARGE; HUMAN; INTERNATIONAL NORMALIZED RATIO; INTERPERSONAL COMMUNICATION; INVASIVE PROCEDURE; LANGUAGE; LIKERT SCALE; LOGIC; MAINTENANCE THERAPY; MEDICAL SPECIALIST; NARRATIVE; NURSE; OUTPATIENT; PATIENT EDUCATION; PHARMACIST; PHYSICIAN; REIMBURSEMENT; RISK FACTOR; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT REFUSAL; UNSPECIFIED SIDE EFFECT; CONSENSUS DEVELOPMENT; EMERGENCY HEALTH SERVICE; HOSPITALIZATION; MEDICATION THERAPY MANAGEMENT; UNITED STATES;

ANTICOAGULANTS; ELECTRONIC HEALTH RECORDS; EMERGENCY SERVICE, HOSPITAL; HOSPITALIZATION; HUMANS; MEDICATION THERAPY MANAGEMENT; NEW YORK;

EID: 84919673375     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028014555176     Document Type: Article

References (40)

1. Nutescu EA,Wittkowsky AK,Burnett A,Merli GJ,Ansell JE,Garcia DA.Delivery of optimized inpatient antico-agulation therapy: consensus statement from the Antico-agulation Forum.Ann Pharmacother. 2013;47:714-724
2. Birman-Deych E,Radford MJ,Nilasena DS,Gage BF.Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation.Stroke. 2006;37:1070-1074
3. Budnitz DS,Shehab N,Kegler SR,Richards CL.Medication use leading to emergency department visits for adverse drug events in older adults.Ann Intern Med. 2007;147:755-765
4. Budnitz DS,Lovegrove MC,Shehab N,Richards CL.Emergency hospitalizations for adverse drug events in older Americans.N Engl J Med. 2011;365:2002-2012
5. Pazmino PA.Adverse effects of dabigatran.Ann Intern Med. 2012;157:916
6. Uchino K,Hernandez AV.Dabigatran association with higher risk of acute coronary events.Ann Intern Med. 2012;172:397-402
7. Ross B,Miller MA,Ditch K,Tran M.Clinical experience of life-threatening dabigatran-related bleeding at a large, tertiary care, academic medical center: a case series.J Med Toxicol. 2014;10:223-228
8. Castellucci LA,Cameron C,Le Gal G, et al.Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis.BMJ. 2013;347:f5133
9. Goodman SG,Wojdyla DM,Piccini JP, et al.Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation).J Am Coll Cardiol. 2014;63:891-900
10. Department of Health and Human Services, Office of Disease Prevention and Health Promotion. National Action Plan for Adverse Drug Event Prevention. Washington, DC: Department of Health and Human Services, Office of Disease Prevention and Health Promotion. http://www.health.gov/hai/ade.aspAccessed October 3, 2014.
11. Holbrook A,Schulman S,Witt DM, et al.Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest. 2012;141:e152S-e184S
12. Garcia DA,Witt DM,Hylek E, et al.Delivery of optimized anticoagulant therapy: consensus statement from the Anticoagulation Forum.Ann Pharmacother. 2008;42:979-988
13. Hirsh J,Guyatt G,Alber GW,Harrington R,Schunemann HJ.Antithrombotic and thrombolytic therapy.Chest. 2008;133:110S-112S
14. Van Spall HG,Wallentin L,Yusuf S, et al.Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial.Circulation. 2012;126:2309-2316
15. Papaioannou A,Kennedy CC,Campbell G, et al.A team-based approach to warfarin management in long term care: a feasibility study of the MEDeINR electronic decision support system.BMC Geriatr. 2010;10:38
16. Ageno W,Crowther M,Baglin T,Falanga A,Buller H,Palareti G.Selection and assessment of patients treated with the novel oral anticoagulant drugs: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis.J Thromb Haemost. 2013;11:177-179
17. CoagTrak Anticoagulation Management Software. Couma-Care. http://www.coagtrak.com/coumacare.html. Accessed April 29, 2014.
18. Dawn Clinical Software. Transform your anticoagulation service: enhance productivity, patient safety and quality of care. http://www.4s-dawn.com/products/anticoagulation/da-wnac. Accessed April 29, 2014.
19. Standing Stone. http://www.standingstoneinc.com. Accessed April 29, 2014.
20. Point of Care Decision Support. http://www.ptofcare.com/anticoagulation. Accessed April 29, 2014.
21. Nieuwlaat R,Hubers LM,Spyropoulos AC, et al.Randomised comparison of a simple warfarin dosing algo-rithm versus a computerised anticoagulation management system for control of warfarin maintenance therapy.Thromb Haemost. 2012;108:1228-1235
22. Poller L,Keown M,Ibrahim S, et al.A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program.Thromb Haemost. 2009;101:487-494
23. Williams C,Mostashari F,Mertz K,Hogin E,Atwal P.From the Office of the National Coordinator: the strategy for advancing the exchange of health information.Health Aff (Millwood). 2012;31:527-536
24. Final rule with comment period and final rules.Fed Regist. 2013;78:74825-5200
25. Gokak S.The Medicare EHR incentive program in 2014.Bull Am Coll Surg. 2013;98:42-45
26. Pipersburgh J.The push to increase the use of EHR technology by hospitals and physicians in the United States through the HITECH Act and the Medicare incentive program.J Health Care Finance. 2011;38:54-78
27. Stewart EE,Nutting PA,Crabtree BF,Stange KC,Miller WL,Jaen CR.Implementing the patient-centered medical home: observation and description of the national demonstration project.Ann Fam Med. 2010;8:S21-S32
28. DeLucenay A,Schweitzer KM,Krier MA,Myrka A,Triller DM.Evaluation of the quality and safety of anticoagulation before and after implementation of an electronic medical record.Poster presented at: Thrombosis and Hemostasis Summit of North America; Chicago, IL;.
29. Centers for Medicare and Medicaid Services. The Medicare and Medicaid Electronic Health Record (EHR) Incentive Programs: STAGE 2 TOOLKIT, 2013. http://www.cms.gov/Regulations-and-Guidance/Legislation/EHRIncentiveProgra-ms/Downloads/Stage2_Toolkit_EHR_0313.pdf. Accessed May 19, 2014.
30. Kimmel SE,French B,Kasner SE, et al.A pharmacogenetic versus a clinical algorithm for warfarin dosing.N Engl J Med. 2013;369:2283-2293
31. Verhoef TI,Redekop WK,Daly AK,van Schie RMF,de Boer A,Maitland-van der Zee AH.Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon.Br J Clin Pharmacol. 2014;77:626-641
32. Buller HR,Prins MH,Lensin AW, et al.Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.N Engl J Med. 2012;366:1287-1297
33. Lane DA,Lip GY.Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for thrombo-prophylaxis in nonvalvular atrial fibrillation.Circulation. 2012;126:860-865
34. Kim YK,Nieuwlaat R,Connolly SJ, et al.Effect of a simple two-step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range: a pilot study.J Thromb Haemost. 2010;8:101-116
35. Meijer K,Kim YK,Carter D,Schulman S.A prospective study of an aggressive warfarin dosing algorithm to reach and maintain INR 2 to 3 after heart valve surgery.Thromb Haemost. 2011;105:232-238
36. Ryan PJ,Gilbert M,Rose PE.Computer control of anticoagulant dose for therapeutic management.BMJ. 1989;299:1207-1209
37. Douketis JD,Spyropoulos AC,Spencer FA, et al.Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.Chest. 2012;141:e326S-e350S
38. Rosendaal FR,Cannegieter SC,van der Meer FJ,Briet E.A method to determine the optimal intensity of oral anticoagulant therapy.Thromb Haemost. 1993;69:236-239
39. Kucher N,Koo S,Quiroz R, et al.Electronic alerts to prevent venous thromboembolism among hospitalized patients.N Engl J Med. 2005;352:969-977
40. Zeidan AM,Streiff MB,Lau BD, et al.Impact of a venous thromboembolism prophylaxis “smart order set”: improved compliance, fewer events.Am J Hematol. 2013;88:545-549